image
Healthcare - Biotechnology - NASDAQ - US
$ 46.45
-3.23 %
$ 1.95 B
Market Cap
-15.13
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one TARS stock under the worst case scenario is HIDDEN Compared to the current market price of 46.5 USD, Tarsus Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one TARS stock under the base case scenario is HIDDEN Compared to the current market price of 46.5 USD, Tarsus Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one TARS stock under the best case scenario is HIDDEN Compared to the current market price of 46.5 USD, Tarsus Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TARS

image
$58.0$58.0$56.0$56.0$54.0$54.0$52.0$52.0$50.0$50.0$48.0$48.0$46.0$46.0$44.0$44.0$42.0$42.0$40.0$40.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
183 M REVENUE
948.62%
-121 M OPERATING INCOME
15.78%
-116 M NET INCOME
14.97%
-83 M OPERATING CASH FLOW
29.33%
-199 M INVESTING CASH FLOW
-141.67%
155 M FINANCING CASH FLOW
18.81%
78.3 M REVENUE
17.96%
-26.3 M OPERATING INCOME
-7.61%
-25.1 M NET INCOME
-8.68%
-20.7 M OPERATING CASH FLOW
6.90%
-34.9 M INVESTING CASH FLOW
41.35%
137 M FINANCING CASH FLOW
4565.60%
Balance Sheet Tarsus Pharmaceuticals, Inc.
image
Current Assets 357 M
Cash & Short-Term Investments 291 M
Receivables 48.1 M
Other Current Assets 17.3 M
Non-Current Assets 20.3 M
Long-Term Investments 3 M
PP&E 2.87 M
Other Non-Current Assets 14.4 M
77.29 %12.75 %4.58 %3.83 %Total Assets$377.0m
Current Liabilities 80.6 M
Accounts Payable 27.7 M
Short-Term Debt 608 K
Other Current Liabilities 52.3 M
Non-Current Liabilities 71.8 M
Long-Term Debt 71.8 M
Other Non-Current Liabilities 0
18.19 %34.28 %47.12 %Total Liabilities$152.5m
EFFICIENCY
Earnings Waterfall Tarsus Pharmaceuticals, Inc.
image
Revenue 183 M
Cost Of Revenue 12.8 M
Gross Profit 170 M
Operating Expenses 291 M
Operating Income -121 M
Other Expenses -5.02 M
Net Income -116 M
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)183m(13m)170m(291m)(121m)5m(116m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
92.99% GROSS MARGIN
92.99%
-65.90% OPERATING MARGIN
-65.90%
-63.16% NET MARGIN
-63.16%
-51.46% ROE
-51.46%
-30.65% ROA
-30.65%
-40.60% ROIC
-40.60%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tarsus Pharmaceuticals, Inc.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)20192019202020202021202120222022202320232024202420252025
Net Income -116 M
Depreciation & Amortization 1.22 M
Capital Expenditures -1.57 M
Stock-Based Compensation 27.8 M
Change in Working Capital 3.84 M
Others -4.67 M
Free Cash Flow -84.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tarsus Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for TARS of $67.8 , with forecasts ranging from a low of $58 to a high of $84 .
TARS Lowest Price Target Wall Street Target
58 USD 24.87%
TARS Average Price Target Wall Street Target
67.8 USD 45.96%
TARS Highest Price Target Wall Street Target
84 USD 80.84%
Price
Max Price Target
Min Price Target
Average Price Target
90908080707060605050404030302020Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Tarsus Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
3.3 M USD 6
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.2 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. prnewswire.com - 2 weeks ago
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants David Nakasone – Head-Investor Relations Bobby Azamian – Chief Executive Officer and Chairman Aziz Mottiwala – Chief Commercial Officer Jeff Farrow – Chief Financial Officer and Chief Strategy Officer Sesha Neervannan – Chief Operating Officer Conference Call Participants Lachlan Hanbury-Brown – William Blair Andrea Newkirk – Goldman Sachs Pavan Patel – Bank of America Eddie Hickman – Guggenheim Cory Jubinville – LifeSci Capital Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to Tarsus First Quarter 2025 Earnings Conference Call. seekingalpha.com - 2 weeks ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago. zacks.com - 2 weeks ago
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements Generated $78.3 million in net product sales of XDEMVY ® , an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients globenewswire.com - 2 weeks ago
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2 weeks ago
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. globenewswire.com - 3 weeks ago
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® (lotilaner ophthalmic solution) 0.25% in addressing objective measures of disease at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting, taking place April 25-28, 2025, in Los Angeles, Calif. globenewswire.com - 4 weeks ago
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $125.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 14, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com - 2 months ago
Tarsus Announces Proposed $100.0 Million Public Offering IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. globenewswire.com - 2 months ago
Tarsus Pharma: Strong Execution In Xdemvy Commercialization Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project Tarsus' revenue to reach $352M in 2025, driven by expanding sales, Medicare/Medicaid reimbursement, and increasing consumer awareness. Tarsus' pipeline includes promising candidates TP-04 for Ocular Rosacea and TP-05 for Lyme disease, enhancing long-term growth prospects. seekingalpha.com - 2 months ago
Tarsus to Participate in Upcoming Investor Conference IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET. globenewswire.com - 2 months ago
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwala - CCO Seshadri Neervannan - COO Jeff Farrow - CFO and CSO Conference Call Participants Francois Brisebois - Oppenheimer Corey Jubinville - Life Sci Capital Jason Gerberry - Bank of America Oren Livnat - HC Wainright Eddie Hickman - Guggenheim Securities Andrea Newkirk - Goldman Sachs Lachlan Hanbury-Brown - William Blair Operator Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded. seekingalpha.com - 2 months ago
8. Profile Summary

Tarsus Pharmaceuticals, Inc. TARS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.95 B
Dividend Yield 0.00%
Description Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Contact 15440 Laguna Canyon Road, Irvine, CA, 92618 https://www.tarsusrx.com
IPO Date Oct. 16, 2020
Employees 323
Officers Mr. Aziz Mottiwala M.B.A. Chief Commercial Officer Ms. Adrienne Kemp Senior Director of Corporate Communications Mr. Scott Youmans Vice President of Sales Ms. Dianne C. Whitfield M.S.W. Chief Human Resources Officer Dr. Elizabeth Yeu M.D. Chief Medical Officer Dr. Seshadri Neervannan Ph.D. Chief Operating Officer Mr. David Nakasone Head of Investor Relations Dr. Bryan Wahl J.D., M.D. General Counsel & Corporate Secretary Mr. Matthew Rossen M.B.A. Vice President of Marketing Dr. Bobak R. Azamian M.D. Co-Founder, President, Chief Executive Officer & Chairman